A Pharmacovigilance Study of Immune Checkpoint Inhibitor‐Associated Cholangitis: Insights From the FDA Adverse Event Reporting System
From a pharmacovigilance perspective, this study characterizes certain clinical features of ICI-associated cholangitis, elucidates distinct risk profiles across ICI classes, and emphasized the importance of constant monitoring. However, further studies remain essential to fully understand this rare irAE.
Authors
- Haowen Tan (ORCID: https://orcid.org/0009-0007-0754-3373)
- Luping Luo (ORCID: https://orcid.org/0009-0001-4641-2874)
- Ying Chen (ORCID: https://orcid.org/0000-0001-7876-4877)
- Weiwei Lan
- Xuan Ou
Institutions
- Wuzhou Red Cross Hospital (CN)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1111/hepr.70082
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05